BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27567053)

  • 1. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
    Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    Gynecol Oncol; 2016 Nov; 143(2):252-257. PubMed ID: 27567053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
    J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience.
    Salgado-Ceballos I; Ríos J; Pérez-Montiel D; Gallardo L; Barquet-Muñoz S; Salcedo-Hernández R; Pérez-Plasencia C; Herrera LA; Cantú de León DF
    Int J Surg; 2017 May; 41():1-5. PubMed ID: 28315410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
    Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
    Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.
    Ataseven B; Grimm C; Harter P; Prader S; Traut A; Heitz F; du Bois A
    Gynecol Oncol; 2014 Dec; 135(3):435-40. PubMed ID: 25312398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
    Song N; Gao Y
    Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of lymphadenectomy in node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Millan I; Iglesias E
    Int J Gynecol Cancer; 2012 Jul; 22(6):987-92. PubMed ID: 22706223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
    Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Bizzarri N; du Bois A; Fruscio R; De Felice F; De Iaco P; Casarin J; Vizza E; Chiantera V; Corrado G; Cianci S; Magni S; Ferrari D; Giuliani D; Harter P; Ataseven B; Bommert M; Perrone AM; Scambia G; Fagotti A
    Gynecol Oncol; 2021 Jan; 160(1):56-63. PubMed ID: 33168305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.
    Takei Y; Takahashi S; Machida S; Taneichi A; Yoshiba T; Takahashi Y; Yoshida C; Saga Y; Matsubara S; Fujiwara H
    Int J Clin Oncol; 2018 Oct; 23(5):930-935. PubMed ID: 29679177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphadenectomy in surgical stage I epithelial ovarian cancer.
    Svolgaard O; Lidegaard O; Nielsen ML; Nedergaard L; Mosgaard BJ; Lidang M; Mogensen O; Kock K; Blaakaer J; Staehr E; Andersen ES; Grove A; Høgdall C
    Acta Obstet Gynecol Scand; 2014 Mar; 93(3):256-60. PubMed ID: 24447203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?
    Sakai K; Kajiyama H; Umezu T; Shibata K; Mizuno M; Suzuki S; Kawai M; Nagasaka T; Kikkawa F
    J Obstet Gynaecol Res; 2012 Jul; 38(7):1018-23. PubMed ID: 22568659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.